NCT02321111View on ClinicalTrials.gov

The Role of TLR4 on Lipid-induced Insulin Resistance

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

September 30, 2018

Study Completion Date

September 30, 2018

Conditions
Insulin Sensitivity
Interventions
DRUG

Eritoran

Eritoran = E5564 Eritoran is a pharmacologic inhibitor of TLR4.

DRUG

D5W (5% Dextrose in water)

D5W = 5% Dextrose Water Vehicle

Trial Locations (1)

78229

Audie L. Murphy VA Hospital, STVHCS, San Antonio

All Listed Sponsors
lead

The University of Texas Health Science Center at San Antonio

OTHER

NCT02321111 - The Role of TLR4 on Lipid-induced Insulin Resistance | Biotech Hunter | Biotech Hunter